Security Snapshot

ImmunityBio, Inc. - Common Stock, par value $0.0001 per share (IBRX) Institutional Ownership

CUSIP: 45256X103

13F Institutional Holders and Ownership History from Q1 2019 to Q3 2026

13F reference period

Q3 2026

Institutions Reporting

310

Shares (Excl. Options)

132.67MFull value: 132,667,465 · shares · 30 Sep 2026

Price

$9.44

The headline uses the Q3 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0%
Share change
-67,394
Value change
+$1,777,956
Number of holders
310
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
1,150,491,181
SEC-reported price per share
$8.74
Insider filing price
$8.74
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • IBRX - ImmunityBio, Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 45256X103.
  • 310 institutions reported positions in Q3 2026.
  • 1 significant owner is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 403 to 310 between Q2 2026 and Q3 2026.
  • SEC-reported value moved from
    $1.76BFull value: $1,760,157,581 · USD · 30 Jun 2026
    to
    $1.25BFull value: $1,251,111,140 · USD · 30 Sep 2026
    .

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 310 institutions filings for Q3 2026.

Open SEC evidence

Security key

45256X103

13F reference period

Q3 2026

13F holders

310

13D/G owners

1

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
1
Security
IBRX
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Cambridge Equities, LP 65% -2.3% $5,807,587,440 -$453,152 745,518,285 -0.01% Patrick Soon-Shiong 31 Jul 2026
As of 30 Sep 2026, 310 institutional investors reported holding
132.67MFull value: 132,667,465 · shares · 30 Sep 2026
shares of ImmunityBio, Inc. - Common Stock, par value $0.0001 per share (IBRX). This represents 12% of the company’s total
1.15BFull value: 1,150,491,181 · shares · Stored outstanding share count
outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
9%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
STATE STREET CORP 1.8% 21,095,418 0.01% $199,140,746
VANGUARD PORTFOLIO MANAGEMENT LLC 1.7% 19,390,126 0.01% $183,042,789
VANGUARD CAPITAL MANAGEMENT LLC 1.6% 18,804,937 0% $177,518,605
GEODE CAPITAL MANAGEMENT, LLC 0.92% 10,606,654 0.01% $100,145,198
TWO SIGMA INVESTMENTS, LP 0.51% 5,831,161 0.04% $55,046,160
GOLDMAN SACHS GROUP INC 0.36% 4,129,906 0% $38,986,312
VANGUARD FIDUCIARY TRUST CO 0.25% 2,849,900 0.01% $26,903,056
SEB Asset Management AB 0.21% 2,447,150 0.09% $23,101,059
FEDERATED HERMES, INC. 0.17% 1,958,488 0.03% $18,488,127
Woodline Partners LP 0.16% 1,897,189 0.05% $17,909,464
BANK OF AMERICA CORP /DE/ 0.15% 1,722,619 0% $16,261,524
MARSHALL WACE, LLP 0.13% 1,450,259 0.01% $13,690,445
Trexquant Investment LP 0.11% 1,314,015 0.08% $12,404,302
Cetera Investment Advisers 0.11% 1,221,077 0.01% $11,526,967
Affinity Asset Advisors, LLC 0.1% 1,180,000 0.63% $11,139,200
LPL Financial LLC 0.1% 1,178,709 0% $11,127,013
Private Advisor Group, LLC 0.08% 884,599 0.03% $8,350,613
Janus Henderson Group Ltd. 0.08% 873,690 0% $8,245,036
Pictet Asset Management Holding SA 0.07% 832,486 0.01% $7,385,344
Swiss National Bank 0.06% 741,200 0% $6,996,928
Winning Points Advisors, LLC 0.06% 730,458 6.1% $6,909,474
ALLEN HOLDING INC /NY 0.06% 687,571 0.56% $6,490,670
VOLORIDGE INVESTMENT MANAGEMENT, LLC 0.05% 614,315 0.03% $5,799,134
Kercheville Advisors, LLC 0.05% 613,385 1.6% $5,790,356
Invesco Ltd. 0.05% 558,721 0% $5,274,325

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
31
Headline period
Q3 2026
Rows shown
1-25 of 31
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q3 132,667,465 $1,251,111,140 +$1,777,956 $9.44 310
2026 Q2 201,150,387 $1,760,157,581 +$200,933,869 $8.76 403
2026 Q1 178,067,821 $1,362,861,564 +$100,105,542 $7.67 382
2025 Q4 167,498,886 $331,914,340 +$45,128,854 $1.98 267
2025 Q3 149,650,186 $368,148,509 +$61,432,781 $2.46 258
2025 Q2 124,100,473 $327,790,828 +$117,120,227 $2.64 236
2025 Q1 79,547,067 $239,251,849 -$5,452,987 $3.01 205
2024 Q4 82,639,855 $211,622,425 +$33,803,467 $2.56 193
2024 Q3 68,558,924 $255,147,599 +$21,750,911 $3.72 172
2024 Q2 61,630,296 $389,584,078 -$21,451,973 $6.32 188
2024 Q1 66,215,691 $355,583,288 +$50,300,460 $5.37 157
2023 Q4 57,525,605 $288,814,721 +$55,491,609 $5.02 141
2023 Q3 49,844,823 $84,098,555 +$17,530,681 $1.69 128
2023 Q2 38,816,393 $107,856,591 -$8,601,646 $2.78 108
2023 Q1 46,154,939 $83,993,343 -$34,886,181 $1.82 141
2022 Q4 49,991,144 $253,404,020 +$54,026,855 $5.07 134
2022 Q3 39,497,245 $196,456,912 +$32,509,458 $4.97 117
2022 Q2 33,071,782 $123,053,543 -$11,174,770 $3.72 124
2022 Q1 35,583,839 $199,726,649 +$5,888,206 $5.61 135
2021 Q4 34,419,957 $209,314,595 +$13,197,046 $6.08 127
2021 Q3 31,920,475 $310,877,791 +$41,850,403 $9.74 118
2021 Q2 27,315,269 $390,084,556 +$155,924,275 $14.28 115
2021 Q1 15,930,587 $378,240,945 +$377,213,945 $23.74 112
2020 Q4 100 $1,000 $10.00 1
2020 Q3 100 $1,000 $10.00 1
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .